Neurocrine Biosciences Pursues Major Acquisition

Neurocrine Biosciences Pursues Major Acquisition
Neurocrine Biosciences is advancing toward a significant acquisition of Soleno Therapeutics in a deal valued at over $2.5 billion. This strategic move would bring Soleno's groundbreaking therapy into Neurocrine's expanding portfolio, strengthening the company's position in rare disease treatment markets. Soleno Therapeutics has developed and commercialized a first-in-class medication designed to treat hyperphagia, a condition characterized by extreme and uncontrollable hunger associated with Prader-Willi syndrome. This rare genetic disorder affects approximately one in fifteen thousand births and currently lacks effective pharmaceutical treatments for this specific symptom. The drug represents a significant medical advancement for patients suffering from this debilitating condition.